Achieving clinically meaningful response in endometriosis pain symptoms is associated with improvements in health-related quality of life and work productivity: analysis of 2 phase III clinical trials
- PMID: 31759891
- DOI: 10.1016/j.ajog.2019.11.1255
Achieving clinically meaningful response in endometriosis pain symptoms is associated with improvements in health-related quality of life and work productivity: analysis of 2 phase III clinical trials
Abstract
Background: Endometriosis-related pain symptoms have a negative impact on health-related quality of life and productivity. In fact, as endometriosis-related symptom severity and the number of symptoms experienced increases, health-related quality of life decreases. Dysmenorrhea and nonmenstrual pelvic pain are prominent symptoms experienced by women with endometriosis and were shown to have improved with the oral, nonpeptide gonadotropin-releasing hormone antagonist, elagolix.
Objective: The objective of this post hoc analysis was to address the question of if patients show a clinical response (in dysmenorrhea or nonmenstrual pelvic pain), do they also have improvements in health-related quality of life and in productivity?
Study design: This post hoc analysis used data from the Elaris Endometriosis-I and Elaris Endometriosis-II phase III, randomized, placebo-controlled studies. A surgical diagnosis of endometriosis (in the past 10 years), premenopausal, aged 18-49 years, and moderate to severe endometriosis-associated pain were among the inclusion criteria for both trials. Women self-reported pain daily using a scale ranging from 0 (no pain) to 3 (severe pain); daily pain was assigned to either dysmenorrhea or nonmenstrual pelvic pain based on self-reported bleeding on that particular day. In addition, their self-reported endometriosis-associated pain must have been an average of moderate or severe during the month leading to baseline for inclusion in the trial program. Patients were characterized as achieving a clinical response for dysmenorrhea or nonmenstrual pelvic pain (ie, responder or nonresponder), which was defined as women who did not have an increase in analgesic use and who met the pain reduction score threshold at month 3. Pain reduction score thresholds were defined separately for dysmenorrhea and nonmenstrual pelvic pain in the trial using receiver-operating characteristics analysis. Health-related quality of life was assessed using the Endometriosis Health Profile-30; work productivity was assessed using the Health-Related Productivity Questionnaire.
Results: Women enrolled in Elaris Endometriosis-I (n = 871) and Elaris Endometriosis-II (n = 815) were included in this analysis. Patients with a clinical response during treatment to dysmenorrhea or nonmenstrual pelvic pain also experienced a meaningful improvement in all domains of the Endometriosis Health Profile-30 at month 3. Patients who did not show a dysmenorrhea or nonmenstrual pelvic pain clinical response at month 3 did not exhibit mean improvements in Endometriosis Health Profile-30 domain scores that indicate an Endometriosis Health Profile-30 responder. Productivity improved among dysmenorrhea clinical responders. In the Elaris Endometriosis-I study, clinical responders lost a total of 5.9 hours compared with a total of 13.0 hours for nonresponders of employment-related work at month 3 (P < .0001). Among women in the Elaris Endometriosis-II study, a total of 4.1 hours and 10.4 employment-related hours were lost at month 3 for dysmenorrhea responders vs nonresponders (P < .001). Similar results were obtained when analyzed by non-enstrual pelvic pain responder status.
Conclusion: Women with moderate to severe endometriosis-related pain, who are clinical responders based on dysmenorrhea and nonmenstrual pelvic pain, also experience significant and clinically meaningful improvement in health-related quality of life and productivity as measured by the Endometriosis Health Profile-30 and Health-Related Productivity Questionnaire, respectively.
Keywords: Endometriosis Health Profile-30; Health-Related Productivity Questionnaire; absenteeism; endometriosis; health-related quality of life.
Copyright © 2019 The Author(s). Published by Elsevier Inc. All rights reserved.
Similar articles
-
Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist.N Engl J Med. 2017 Jul 6;377(1):28-40. doi: 10.1056/NEJMoa1700089. Epub 2017 May 19. N Engl J Med. 2017. PMID: 28525302 Clinical Trial.
-
Long-Term Outcomes of Elagolix in Women With Endometriosis: Results From Two Extension Studies.Obstet Gynecol. 2018 Jul;132(1):147-160. doi: 10.1097/AOG.0000000000002675. Obstet Gynecol. 2018. PMID: 29889764 Clinical Trial.
-
Efficacy, tolerability, and bone density outcomes of elagolix with add-back therapy for endometriosis-associated pain: twelve months of an ongoing randomized phase 3 trial.Am J Obstet Gynecol. 2024 Dec;231(6):630.e1-630.e13. doi: 10.1016/j.ajog.2024.06.040. Epub 2024 Jun 30. Am J Obstet Gynecol. 2024. PMID: 38955323 Clinical Trial.
-
Clinical evaluation of the oral gonadotropin-releasing hormone-antagonist elagolix for the management of endometriosis-associated pain.Pain Manag. 2019 Sep;9(5):497-515. doi: 10.2217/pmt-2019-0010. Epub 2019 Aug 22. Pain Manag. 2019. PMID: 31434540 Review.
-
A Clinician's Guide to the Treatment of Endometriosis with Elagolix.J Womens Health (Larchmt). 2021 Apr;30(4):569-578. doi: 10.1089/jwh.2019.8096. Epub 2020 Sep 22. J Womens Health (Larchmt). 2021. PMID: 32975461 Free PMC article. Review.
Cited by
-
Efficacy and safety of a novel pain management device, AT-04, for endometriosis-related pain: study protocol for a phase III randomized controlled trial.Reprod Health. 2024 Jan 26;21(1):12. doi: 10.1186/s12978-024-01739-8. Reprod Health. 2024. PMID: 38279180 Free PMC article.
-
Elagolix in the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.Expert Rev Clin Pharmacol. 2021 Apr;14(4):427-437. doi: 10.1080/17512433.2021.1900726. Epub 2021 Mar 15. Expert Rev Clin Pharmacol. 2021. PMID: 33682578 Free PMC article. Review.
-
A systematic review to determine use of the Endometriosis Health Profiles to measure quality of life outcomes in women with endometriosis.Hum Reprod Update. 2024 Mar 1;30(2):186-214. doi: 10.1093/humupd/dmad029. Hum Reprod Update. 2024. PMID: 38007607 Free PMC article.
-
Endometriosis: A Disease with Few Direct Treatment Options.Molecules. 2022 Jun 23;27(13):4034. doi: 10.3390/molecules27134034. Molecules. 2022. PMID: 35807280 Free PMC article. Review.
-
Interdisciplinary model-informed drug development for extending duration of elagolix treatment in patients with uterine fibroids.Br J Clin Pharmacol. 2022 Dec;88(12):5257-5268. doi: 10.1111/bcp.15440. Epub 2022 Jul 11. Br J Clin Pharmacol. 2022. PMID: 35695781 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous